Novo Nordisk is undercutting Eli Lilly on obesity drugs for cash-pay patients as it tries to claw back a larger share of the US market https://t.co/Q72oSTuLO8 ...

Novo shares rose after the Danish drugmaker withdrew from a $10 billion takeover battle for obesity drug developer Metsera https://t.co/cD80Gl7QNn ...

Industry News - Trump announces steep discounts on obesity drugs [1] Market Impact - Potential impact on pharmaceutical companies and healthcare providers [1]